<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">TANIGUCHI, YOSHIE</style></author><author><style face="normal" font="default" size="100%">NISHIZAWA, TAKASHI</style></author><author><style face="normal" font="default" size="100%">HONDA, TERUKO</style></author><author><style face="normal" font="default" size="100%">YOSHIOKA, NORIKO</style></author><author><style face="normal" font="default" size="100%">INAGAWA, HIROYUKI</style></author><author><style face="normal" font="default" size="100%">KOHCHI, CHIE</style></author><author><style face="normal" font="default" size="100%">SOMA, GEN-ICHIRO</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Development and Potential Use of a Monoclonal Antibody to the Lipopolysaccharide of &lt;em&gt;Pantoea agglomerans&lt;/em&gt; (IP-PA1)</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">3701-3706</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><issue><style face="normal" font="default" size="100%">6A</style></issue><abstract><style  face="normal" font="default" size="100%">Background: The lipopolysaccharide of Pantoea agglomerans (IP-PA1) has been shown to be effective and safe in the prevention of various diseases, such as bacterial or viral infection, lifestyle-related diseases, when administered transdermally or orally. To clarify the mechanisms of the preventive or therapeutic effect induced by IP-PA1, we tried to establish a monoclonal antibody to detect IP-PA1. The enzyme-linked immunosorbent assay (ELISA) was used to measure the amount of IP-PA1. Materials and Methods: Antibodies were raised by immunization using heat-killed Pantoea agglomerans and screening was conducted to isolate monoclonal antibodies specific to IP-PA1. Results: Six kinds of IP-PA1 specific monoclonal antibodies with different epitopes were established. An ELISA using the monoclonal antibodies was successfully established which could specifically detect IP-PA1. Conclusion: By use of this ELISA, the staple food content and pharmacodynamic analysis of IP-PA1 could be conveniently estimated. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved</style></abstract></record></records></xml>